Covalon Technologies Stock Price, News & Analysis (CVE:COV)

C$4.50 0.08 (1.81 %)
(As of 11/17/2017 06:47 AM ET)
Previous CloseC$4.42
Today's RangeC$4.25 - C$4.63
52-Week RangeC$1.55 - C$5.00
Volume14,050 shs
Average Volume13,437 shs
Market CapitalizationC$96.61 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.11

About Covalon Technologies (CVE:COV)

Covalon Technologies logoCovalon Technologies Ltd. researches, develops, manufactures, markets, and licenses medical products in the areas of advanced wound care, infection management, and surgical procedures worldwide. The company offers Collagen Matrix platform to develop products for the treatment of donor and graft sites, traumatic and surgical wounds, and first and second degree burns, as well as diabetic, pressure, and venous ulcers; Antimicrobial Silicone Adhesive platform, a pre-surgical, post-surgical, and vascular access products; and medical coating platform CovaCoat, a technology that provides photochemical process for covalently linking coating molecules to various medical device surfaces. Its medical coatings deliver infection control, therapeutic delivery, and lubricity. The company also provides services, such as feasibility studies, product formulation, prototype testing, validation, regulatory clearances, and manufacturing. In addition, it offers wound care products comprising ColActive Plus Ag collagen matrix dressings; ColActive Transfer wound contact layers; and CovaWound advanced wound care dressings. Further, the company provides IV Clear and SurgiClear antimicrobial silicone dressings. It offers its technologies, products, and services to medical device companies; healthcare providers, such as hospitals, wound care centers, burn centers, extended/alternate care facilities, acute care facilities, home health care agencies, and physicians’ offices; and individual consumers. Covalon Technologies Ltd. is headquartered in Mississauga, Canada.


Industry, Sector and Symbol:
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Sector: Healthcare
  • Symbol: CVE:COV
  • CUSIP: N/A
  • Web: www.covalon.com
Profitability:
  • Trailing EPS: C($0.05)
  • Net Margins: 9.17%
  • Return on Equity: 31.45%
  • Return on Assets: 22.05%
Misc:
  • Outstanding Shares: 21,342,000
 

Frequently Asked Questions for Covalon Technologies (CVE:COV)

What is Covalon Technologies' stock symbol?

Covalon Technologies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "COV."

When will Covalon Technologies make its next earnings announcement?

Covalon Technologies is scheduled to release their next quarterly earnings announcement on Monday, January, 29th 2018. View Earnings Estimates for Covalon Technologies.

Who are some of Covalon Technologies' key competitors?

Who are Covalon Technologies' key executives?

Covalon Technologies' management team includes the folowing people:

  • Abe Schwartz, Chairman of the Board
  • Brian E. Pedlar, President, Chief Executive Officer, Director
  • Danny Brannagan, Chief Financial Officer
  • Valerio DiTizio, Chief Scientific Officer
  • Kim Crooks, Vice President - Operations
  • John Hands, Senior Director - Global Marketing
  • Elinor Caplan, Director
  • Gale Pollock, Director
  • Martin C. Bernholtz, Independent Director
  • Ian David Brindle, Independent Director

How do I buy Covalon Technologies stock?

Shares of Covalon Technologies and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Covalon Technologies' stock price today?

One share of Covalon Technologies stock can currently be purchased for approximately C$4.50.

How big of a company is Covalon Technologies?

Covalon Technologies has a market capitalization of C$96.61 million.

How can I contact Covalon Technologies?

Covalon Technologies' mailing address is 1660 Tech Ave Unit 5, MISSISSAUGA, ON L4W 5S7, Canada. The company can be reached via phone at +1-905-5688400.


MarketBeat Community Rating for Covalon Technologies (CVE COV)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  14 (Vote Outperform)
Underperform Votes:  12 (Vote Underperform)
Total Votes:  26
MarketBeat's community ratings are surveys of what our community members think about Covalon Technologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Covalon Technologies (CVE:COV)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for Covalon Technologies (CVE:COV)

Price Target History for Covalon Technologies (CVE:COV)

Analysts' Ratings History for Covalon Technologies (CVE:COV)

Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Covalon Technologies (CVE:COV)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Covalon Technologies (CVE:COV)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Covalon Technologies (CVE:COV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Covalon Technologies (CVE COV)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Covalon Technologies (CVE:COV)

Latest Headlines for Covalon Technologies (CVE COV)

Source:

Social Media

Financials

Financials are not available for this stock.

Chart

Covalon Technologies (CVE COV) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.